We sought to assess for impact on management trends in new patients presenting to our institution with stress urinary incontinence (SUI) following the release of the FDA Health Notification in July 2011 for vaginal mesh.
Materials and methods:
Chart analysis was performed on patients assigned a primary International Classification of Diseases (ICD-9) diagnosis code of 625.6 for SUI at initial consultation by two providers at our institution between June 1, 2010 and November 30, 2014. Rates of treatment and types of procedures performed were analyzed: urethral bulking, mesh sling, or pubovaginal sling.
Results:
A total of 333 new patients were identified with an increasing trend over time. One hundred and twenty-three patients underwent 153 procedures for stress incontinence. The mean proportion that had a procedure per six-month period was 37%, with decreasing proportions over time. Initially all procedures were midurethral mesh slings, with a decline at the time of and after the notification, and a temporary increase in bulking procedures. Subsequently, there was a rise again in sling placement, namely with an increase in pubovaginal slings. Of the 20 pubovaginal slings placed, 13 were placed in patients who had a prior anti-incontinence surgery (eight for sling failure, vaginal mesh, or fixed urethra, and two in patients with mesh extrusion/erosion). Seven were performed in patients who had never had prior surgery (two for very high-grade incontinence, two with urethral diverticulectomy, and three in patients who expressed concern about mesh).
Conclusions:
Although there were an increasing number of patients seen for management of SUI over time, there was a progressive decrease in the proportion of patients having anti-incontinence procedures after release of the FDA notification. There was an overall decrease in the use of mesh slings and an increase in bulking, and more notably, placement of pubovaginal slings.
HannestadYSRortveitGSandvikHet al. A community-based epidemiological survey of female urinary incontinence: The Norwegian EPICONT study. Epidemiology of incontinence in the county of Nord-Trøndelag. J Clin Epidemiol2000; 53: 1150–1157.
2.
FritelXRingaVQuiboeufEet al. Female urinary incontinence, from pregnancy to menopause: A review of epidemiological and pathophysiological findings. Acta Obstet Gynecol Scand2012; 91: 901–910.
3.
BotleroRUrquhartDMDavisSRet al. Prevalence and incidence of urinary incontinence in women: Review of the literature and investigation of methodological issues. Int J Urol2008; 15: 230–234.
WuJMKawasakiAHundleyAFet al. Predicting the number of women who will undergo incontinence and prolapse surgery, 2010 to 2050. Am J Obstet Gynecol2011; 205: 230.e1–230.e5.
6.
HillaryCJOsmanNChappleC.Considerations in the modern management of stress incontinence resulting from intrinsic sphincter deficiency. World J Urol2015; 33: 1251–1256.
7.
AngerJTWeinbergAEAlboMEet al. Trends in surgical management of stress urinary incontinence among female Medicare beneficiaries. Urology2009; 74: 283–287.
8.
FunkMJLevinPJWuJM.Trends in the surgical management of stress urinary incontinence. Obstet Gynecol2012; 119: 845–851.
9.
Rogo-GuptaLLitwinMSSaigalCSet al. Trends in the surgical management of stress urinary incontinence among female Medicare beneficiaries, 2002–2007. Urology2013; 82: 38–42.
ReynoldsWSGoldKPNiSet al. Immediate effects of the initial FDA notification on the use of surgical mesh for pelvic organ prolapse surgery in Medicare beneficiaries. Neurourol Urodyn2013; 32: 330–335.
14.
Rogo-GuptaLRodriguezLVLitwinMSet al. Trends in surgical mesh use for pelvic organ prolapse from 2000 to 2010. Obstet Gynecol2012; 120: 1105–1115.
15.
FunkMJSiddiquiNYPateVet al. Sling revision/removal for mesh erosion and urinary retention: Long-term risk and predictors. Am J Obstet Gynecol2013; 208: 73.e1–73.e7.
16.
KhanAEilberKClemensJQet al. Trends in management of pelvic organ prolapse among female Medicare beneficiaries. Am J Obstet Gynecol2015; 212: 463.e1–463.e8.
17.
WuJMMatthewsCAConoverMMet al. Lifetime risk of stress urinary incontinence or pelvic organ prolapse surgery. Obstet Gynecol2014; 123: 1201–1206.
18.
RockJAJonesHW (eds) Te Linde’s operative gynecology. 8th ed.Philadelphia: Lippincott Williams & Wilkins, 1997.
19.
AldridgeAH.Transplantation of fascia for relief of urinary incontinence. Am J Ob Gynecol1942; 44: 398–411.
20.
PereyraAJ.A simplified surgical procedure for the correction of stress incontinence in women. Western J Surg Obstet Gynecol1959; 67: 223–226.
21.
BurchJC.Urethrovaginal fixation to Cooper’s ligament for correction of stress incontinence, cystocele, and prolapse. Am J Obstet Gynecol1961; 81: 281–290.
22.
UlmstenUHerikssonLJohnsonPet al. An ambulatory surgical procedure under local anesthesia for treatment of female urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct1996; 7: 81–85.
23.
PetrosPPapadimitriouJ.Evolution of midurethral and other mesh slings—critical analysis. Neurourol Urodyn2013; 32: 399–406.
24.
WardKLHiltonP.A prospective multicenter randomized trial of tension-free vaginal tape and colposuspension for primary urodynamic stress incontinence: Two-year follow-up. Am J Obstet Gynecol2004; 190: 324–331.
25.
LiapisABakasPCreatsasG.Burch colposuspension and tension-free vaginal tape in the management of stress urinary incontinence in women. Eur Urol2002; 41: 469–473.
26.
AnkardalMJarbrinkKMilsomIet al. Comparison of health care costs for open Burch colposuspension, laparoscopic colposuspension and tension-free vaginal tape in the treatment of female urinary incontinence. Neurourol Urodyn2007; 26: 761–766.
27.
Kaelin-GambirasioIJacobSBoulvainMet al. Complications associated with transobturator sling procedures: Analysis of 233 consecutive cases with a 27 months follow-up. BMC Womens Health2009; 9: 28.
28.
DomingoSAlamaPRuizNet al. Diagnosis, management, and prognosis of vaginal erosion after trans-obturator sub urethral tape procedure using a non-woven thermally bonded, polypropylene mesh. J Urol2005; 173: 1627–1630.
29.
BrubakerLNortonPAAlboMEet al. Adverse events over two years after retropubic or transobturator midurethral sling surgery: Findings from the Trial of Midurethral Slings (TOMUS) study. Am J Obstet Gynecol2011; 205: 498.e1–498.e6.
30.
AshokKPetriE.Failures and complications in pelvic floor surgery. World J Urol2012; 30: 487–494.
31.
FendersonJLWashingtonBBHamptonBSet al. Unrecognized bladder perforation leading to severe progressive cellulitis and candidal infection. Fem Pelvic Med Recons Surg2012; 18: 130–131.
32.
RardinCRRosenblattPLKohliNet al. Release of tension-free vaginal tape for the treatment of refractory postoperative voiding dysfunction. Obstet Gynecol2002; 100 (5Pt 1): 898–902.
33.
HammadFTKennedy-SmithARobinsonRG.Erosions and urinary retention following polypropylene synthetic sling: Australasian survey. Eur Urol2005; 47: 641–646.
34.
DooCKHongBChungBJet al. Five-year outcomes of the tension-free vaginal tape procedure for treatment of female stress urinary incontinence. Eur Urol2006; 50: 333–338.
35.
WangWZhuLLangJ.Transobturator tape procedure versus tension-free vaginal tape for treatment of stress urinary incontinence. Int J Gynaecol Obstet2009; 104: 113–116.
36.
MazouniCKarsentyGBretelleFet al. Urinary complications and sexual function after the tension-free vaginal tape procedure. Acta Obstet Gynecol Scand2004; 83: 955–961.
37.
CholhanHJHutchingsTBRooneyKE.Dyspareunia associated with paraurethral banding in the transobturator sling. Am J Obstet Gynecol2010; 202: 481.e1–481.e5.
38.
RothTM.Management of persistent groin pain after transobturator slings. Int Urogynecol J Pelvic Floor Dysfunct2007; 18: 1371–1373.
KoskiMERovnerES.Implications of the FDA statement on transvaginal placement of mesh: The aftermath. Curr Urol Rep2014; 15: 380.
42.
KoskiMEChamberlainJRosoffJet al. Patient perception of transvaginal mesh and the media. Urology2104; 84: 575–582.
43.
TenggardjajaCFMooreCKVasavadaSPet al. Evaluation of patients’ perceptions of mesh usage in female pelvic medicine and reconstructive surgery. Urology2015; 85: 326–332.
44.
MyersECraneAKGellerEJet al. Evaluating the early impact of the FDA Safety Communication on use of surgical mesh. Female Pelvic Med Reconst Surg2012; 18: S197.
45.
ClemonsJLWeinsteinMGuessMKet al. Impact of the 2011 FDA transvaginal mesh safety update on AUGS members’ use of synthetic mesh and biologic grafts in pelvic reconstructive surgery. Fem Pelvic Med Reconst Surg2013; 19: 191–198.
46.
RacGYoungerAClemensJQet al. Stress urinary incontinence surgery trends in academic female pelvic medicine and reconstructive surgery urology practice in the setting of the Food and Drug Administration public health notifications. Neurourol Urodyn. Epub ahead of print 26 July 2016. DOI: 10.1002/nau.23080.
